{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:52:08Z","timestamp":1791337928372,"version":"4.3.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001868","name":"National Science Council","doi-asserted-by":"publisher","award":["NSTC 114-2321-B-182A-006"],"award-info":[{"award-number":["NSTC 114-2321-B-182A-006"]}],"id":[{"id":"10.13039\/501100001868","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04476-y","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T03:05:14Z","timestamp":1783911914000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Survival outcomes of conversion curative therapy following atezolizumab\u2013bevacizumab in advanced hepatocellular carcinoma"],"prefix":"10.1007","volume":"75","author":[{"given":"Ying-Hsin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Chao","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Hung","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Houng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Hung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Nan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Chi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1646-9519","authenticated-orcid":false,"given":"Chao-Hung","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"4476_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of Incidence and mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"4476_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101571","volume":"7","author":"E Mauro","year":"2025","unstructured":"Mauro E, de Castro T, Zeitlhoefler M, Sung MW, Villanueva A, Mazzaferro V, Llovet JM (2025) Hepatocellular carcinoma: epidemiology, diagnosis and treatment. JHEP Rep 7:101571. https:\/\/doi.org\/10.1016\/j.jhepr.2025.101571","journal-title":"JHEP Rep"},{"key":"4476_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A et al (2021) Hepatocellular carcinoma. Nat Rev Dis Primers 7:6. https:\/\/doi.org\/10.1038\/s41572-020-00240-3","journal-title":"Nat Rev Dis Primers"},{"key":"4476_CR4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","volume":"82","author":"European Association for the Study of the L","year":"2025","unstructured":"European Association for the Study of the L (2025) EASL clinical practice guidelines on the management of hepatocellular carcinoma. J Hepatol 82:315\u2013374. https:\/\/doi.org\/10.1016\/j.jhep.2024.08.028","journal-title":"J Hepatol"},{"key":"4476_CR5","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/HEP.0000000000001269","volume":"82","author":"TH Taddei","year":"2025","unstructured":"Taddei TH, Brown DB, Yarchoan M, Mendiratta-Lala M, Llovet JM (2025) Critical update: AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 82:272\u2013274. https:\/\/doi.org\/10.1097\/HEP.0000000000001269","journal-title":"Hepatology"},{"key":"4476_CR6","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J et al (2022) BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol 76:681\u2013693. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.018","journal-title":"J Hepatol"},{"key":"4476_CR7","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M et al (2020) Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 382:1894\u20131905. https:\/\/doi.org\/10.1056\/NEJMoa1915745","journal-title":"N Engl J Med"},{"key":"4476_CR8","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1159\/000526163","volume":"11","author":"M Kudo","year":"2022","unstructured":"Kudo M (2022) Atezolizumab plus Bevacizumab followed by curative conversion (ABC Conversion) in Patients with Unresectable, TACE-unsuitable Intermediate-stage Hepatocellular Carcinoma. Liver Cancer 11:399\u2013406. https:\/\/doi.org\/10.1159\/000526163","journal-title":"Liver Cancer"},{"key":"4476_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215475","author":"M Kudo","year":"2021","unstructured":"Kudo M (2021) Changing the treatment paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab combination therapy. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13215475","journal-title":"Cancers (Basel)"},{"key":"4476_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-015-1565-2","volume":"8","author":"J Takada","year":"2015","unstructured":"Takada J, Hidaka H, Nakazawa T et al (2015) Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma. BMC Res Notes 8:609. https:\/\/doi.org\/10.1186\/s13104-015-1565-2","journal-title":"BMC Res Notes"},{"key":"4476_CR11","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1159\/000546899","volume":"15","author":"M Kudo","year":"2026","unstructured":"Kudo M, Ueshima K, Tsuchiya K et al (2026) Primary analysis of a phase II study of Atezolizumab plus Bevacizumab for TACE-unsuitable patients with Tumor Burden beyond Up-To-seven criteria in intermediate-stage Hepatocellular Carcinoma: REPLACEMENT study. Liver Cancer 15:104\u2013116. https:\/\/doi.org\/10.1159\/000546899","journal-title":"Liver Cancer"},{"key":"4476_CR12","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1159\/000547230","volume":"15","author":"GH Choi","year":"2025","unstructured":"Choi GH, Kim HS, Luu M et al (2025) Curative treatment after immunotherapy leads to excellent outcomes in patients with Hepatocellular Carcinoma. Liver Cancer 15:193\u2013204. https:\/\/doi.org\/10.1159\/000547230","journal-title":"Liver Cancer"},{"key":"4476_CR13","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.dld.2012.10.019","volume":"45","author":"JH Wang","year":"2013","unstructured":"Wang JH, Kuo YH, Wang CC, Chen CL, Cheng YF, Hsu HC, Lu SN (2013) Surgical resection improves the survival of selected hepatocellular carcinoma patients in Barcelona clinic liver cancer stage C. Dig Liver Dis 45:510\u2013515. https:\/\/doi.org\/10.1016\/j.dld.2012.10.019","journal-title":"Dig Liver Dis"},{"key":"4476_CR14","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","volume":"11","author":"M Omata","year":"2017","unstructured":"Omata M, Cheng AL, Kokudo N et al (2017) Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 11:317\u2013370. https:\/\/doi.org\/10.1007\/s12072-017-9799-9","journal-title":"Hepatol Int"},{"key":"4476_CR15","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1159\/000509424","volume":"9","author":"J Zhou","year":"2020","unstructured":"Zhou J, Sun H, Wang Z et al (2020) Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition). Liver Cancer 9:682\u2013720. https:\/\/doi.org\/10.1159\/000509424","journal-title":"Liver Cancer"},{"key":"4476_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000143","volume":"7","author":"K Seif El Dahan","year":"2023","unstructured":"Seif El Dahan K, Reczek A, Daher D et al (2023) Multidisciplinary care for patients with HCC: a systematic review and meta-analysis. Hepatol Commun 7:e0143. https:\/\/doi.org\/10.1097\/HC9.0000000000000143","journal-title":"Hepatol Commun"},{"key":"4476_CR17","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.jhep.2021.07.004","volume":"75","author":"J Bruix","year":"2021","unstructured":"Bruix J, Chan SL, Galle PR, Rimassa L, Sangro B (2021) Systemic treatment of hepatocellular carcinoma: an EASL position paper. J Hepatol 75:960\u2013974. https:\/\/doi.org\/10.1016\/j.jhep.2021.07.004","journal-title":"J Hepatol"},{"key":"4476_CR18","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000514174","volume":"10","author":"M Kudo","year":"2021","unstructured":"Kudo M, Kawamura Y, Hasegawa K et al (2021) Management of Hepatocellular Carcinoma in Japan: JSH consensus statements and recommendations 2021 update. Liver Cancer 10:181\u2013223. https:\/\/doi.org\/10.1159\/000514174","journal-title":"Liver Cancer"},{"key":"4476_CR19","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3350\/cmh.2022.0294","volume":"28","author":"A Korean Liver Cancer","year":"2022","unstructured":"Korean Liver Cancer A, National Cancer Center K (2022) 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol 28:583\u2013705. https:\/\/doi.org\/10.3350\/cmh.2022.0294","journal-title":"Clin Mol Hepatol"},{"key":"4476_CR20","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jfma.2017.09.007","volume":"117","author":"g Surveillance","year":"2018","unstructured":"Surveillance g, Diagnosis g, Staging g et al (2018) Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan liver cancer association and the gastroenterological society of Taiwan. J Formos Med Assoc 117:381\u2013403. https:\/\/doi.org\/10.1016\/j.jfma.2017.09.007","journal-title":"J Formos Med Assoc"},{"key":"4476_CR21","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3350\/cmh.2023.0099","volume":"29","author":"Y Cho","year":"2023","unstructured":"Cho Y, Kim BH, Park JW (2023) Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: an Asian perspective comparison. Clin Mol Hepatol 29:252\u2013262. https:\/\/doi.org\/10.3350\/cmh.2023.0099","journal-title":"Clin Mol Hepatol"},{"key":"4476_CR22","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng AL, Qin S, Ikeda M et al (2022) Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol 76:862\u2013873. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.030","journal-title":"J Hepatol"},{"key":"4476_CR23","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/hepr.13734","volume":"52","author":"A Hiraoka","year":"2022","unstructured":"Hiraoka A, Kumada T, Tada T et al (2022) Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria - Multicenter analysis. Hepatol Res 52:308\u2013316. https:\/\/doi.org\/10.1111\/hepr.13734","journal-title":"Hepatol Res"},{"key":"4476_CR24","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000528272","volume":"12","author":"M Kudo","year":"2023","unstructured":"Kudo M, Finn RS, Galle PR et al (2023) IMbrave150: efficacy and safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona clinic liver cancer stage B Unresectable Hepatocellular Carcinoma: an exploratory analysis of the phase III study. Liver Cancer 12:238\u2013250. https:\/\/doi.org\/10.1159\/000528272","journal-title":"Liver Cancer"},{"key":"4476_CR25","doi-asserted-by":"publisher","first-page":"4475","DOI":"10.1002\/cncr.25960","volume":"117","author":"K Uchino","year":"2011","unstructured":"Uchino K, Tateishi R, Shiina S et al (2011) Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer 117:4475\u20134483. https:\/\/doi.org\/10.1002\/cncr.25960","journal-title":"Cancer"},{"key":"4476_CR26","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s10585-014-9641-x","volume":"31","author":"JI Lee","year":"2014","unstructured":"Lee JI, Kim JK, Kim DY, Ahn SH, Park JY, Kim SU, Kim BK, Han KH, Lee KS (2014) Prognosis of hepatocellular carcinoma patients with extrahepatic metastasis and the controllability of intrahepatic lesions. Clin Exp Metastasis 31:475\u2013482. https:\/\/doi.org\/10.1007\/s10585-014-9641-x","journal-title":"Clin Exp Metastasis"},{"key":"4476_CR27","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/j.1440-1746.2011.06917.x","volume":"27","author":"SM Jung","year":"2012","unstructured":"Jung SM, Jang JW, You CR et al (2012) Role of intrahepatic tumor control in the prognosis of patients with hepatocellular carcinoma and extrahepatic metastases. J Gastroenterol Hepatol 27:684\u2013689. https:\/\/doi.org\/10.1111\/j.1440-1746.2011.06917.x","journal-title":"J Gastroenterol Hepatol"},{"key":"4476_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15215115","volume":"15","author":"S Alghamdi","year":"2023","unstructured":"Alghamdi S, Al-Hamoudi W (2023) Hepatocellular Carcinoma: the role of immunotherapy and transplantation in the Era of transplant oncology. Cancers (Basel) 15:5115. https:\/\/doi.org\/10.3390\/cancers15215115","journal-title":"Cancers (Basel)"},{"key":"4476_CR29","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jhep.2024.09.003","volume":"82","author":"P Tabrizian","year":"2025","unstructured":"Tabrizian P, Holzner ML, Ajmera V et al (2025) Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: the multicenter VITALITY study. J Hepatol 82:512\u2013522. https:\/\/doi.org\/10.1016\/j.jhep.2024.09.003","journal-title":"J Hepatol"},{"key":"4476_CR30","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jhep.2024.06.042","volume":"82","author":"MS Rezaee-Zavareh","year":"2025","unstructured":"Rezaee-Zavareh MS, Yeo YH, Wang T et al (2025) Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: a systematic review and individual patient data meta-analysis. J Hepatol 82:107\u2013119. https:\/\/doi.org\/10.1016\/j.jhep.2024.06.042","journal-title":"J Hepatol"},{"key":"4476_CR31","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1111\/liv.15907","volume":"44","author":"T Kikuchi","year":"2024","unstructured":"Kikuchi T, Takeuchi Y, Nouso K et al (2024) Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab. Liver Int 44:1456\u20131463. https:\/\/doi.org\/10.1111\/liv.15907","journal-title":"Liver Int"},{"key":"4476_CR32","doi-asserted-by":"publisher","first-page":"234","DOI":"10.17998\/jlc.2024.05.23","volume":"24","author":"RJD Febro","year":"2024","unstructured":"Febro RJD, Perillo ESS, Kimura AA, Wong SN (2024) Cure can be achieved by conversion to microwave ablation following atezolizumab-bevacizumab therapy in unresectable hepatocellular carcinoma. Journal of Liver Cancer 24:234\u2013242. https:\/\/doi.org\/10.17998\/jlc.2024.05.23","journal-title":"Journal of Liver Cancer"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04476-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04476-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04476-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:25:43Z","timestamp":1791336343000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04476-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["4476"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04476-y","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"12 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was conducted in accordance with the Declaration of Helsinki and with institutional and national regulations. The study protocol was approved by the Institutional Review Board of Chang Gung Memorial Hospital (IRB No.: 202600437B0).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In accordance with national legislation and institutional requirements, the need for written informed consent was waived by the Ethics Committee because of the retrospective nature of the study.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"246"}}